Results 241 to 250 of about 214,376 (295)

Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer

Cancer Treatment Reviews, 2001
The chemo-immunotherapy (CIT) and chemo-adoptive immunotherapy (CAIT) regimens tested in the past decade are summarized. From them we have learned a great deal about the interactions between various chemotherapeutic agents, immune modulating agents and effector cells.
G G, Gomez, R B, Hutchison, C A, Kruse
openaire   +2 more sources

Adoptive Immunotherapy for Malignant Glioma

The Cancer Journal, 2003
Despite remarkable advancements in imaging modalities and treatment options available to patients diagnosed with malignant brain tumors, the prognosis for those with high-grade lesions remains poor. The imprecise mechanisms of currently available treatments to manage these tumors do not spare damage to the normal surrounding brain and often result in ...
Duane A, Mitchell, Peter E, Fecci, John H, Sampson   +2 more
openaire   +2 more sources

Adoptive immunotherapy of HCMV infection

Cytotherapy, 2007
Human cytomegalovirus (HCMV) infection or reactivation is a frequent cause of morbidity and mortality in immunocompromised individuals such as transplant recipients. Primary HCMV infection or reactivation of HCMV from latency is mostly asymptomatic in immunocompetent individuals and is controlled by the host's cell-mediated immune response.
M, Kapp, S M, Tan, H, Einsele, Gu, Grigoleit   +3 more
openaire   +2 more sources

Mononuclear Cell Adoptive Immunotherapy

Hematology/Oncology Clinics of North America, 1994
In contrast with red cells, platelets, and granulocytes, hemotherapy using lymphocytes and monocytes is only beginning to be explored. Blood banks and transfusion services, the traditional sources of expertise in sterile cell processing, storage, and transfusion, have played an integral role in the early technical development of mononuclear cell ...
J H, Lee, H G, Klein
openaire   +2 more sources

Enhancing adoptive immunotherapy of cancer

Expert Opinion on Biological Therapy, 2010
Conventional therapies, including surgery, chemotherapy and radiotherapy have contributed much to cancer treatment. However, these treatment modalities fail in a large proportion of patients, and there is a great need for effective alternate therapies.
Jennifer A, Westwood, Linda J, Berry, Leanne Xj, Wang, Connie Pm, Duong, Hollie J, Pegram, Phillip K, Darcy, Michael H, Kershaw   +6 more
openaire   +2 more sources

Technological advances in adoptive immunotherapy

Drugs of Today, 2005
Adoptive immunotherapy is an attractive and elegant strategy for treating a variety of life-threatening diseases. Several approaches have been developed to generate antigen-specific CD4+ and CD8+ T cells for adoptive T-cell therapy in cancer and infectious diseases.
Mathias, Oelke, Christine, Krueger, Jonathan P, Schneck   +2 more
openaire   +2 more sources

Adoptive Immunotherapy of Ovarian Carcinoma

Gynecologic Oncology, 2002
info:eu-repo/semantics ...
de Gramont, Aimery, Gangji, Diamon, Louvet, Christophe, Garcia, Monserrat, Tardy, D., Romet-Lemonne, Jean-Loup   +5 more
openaire   +2 more sources

Costimulatory approaches to adoptive immunotherapy

Current Opinion in Oncology, 1998
Costimulation is critical for induction of full T-cell effector function, and thus represents an attractive immunotherapeutic approach for the treatment of cancer. This review examines these approaches, including ex vivo T-cell expansion, systemic "delivery" of constimulation, tumors transduced or transfected with costimulatory ligands, and vaccine ...
D N, Liebowitz, K P, Lee, C H, June
openaire   +2 more sources

Adoptive Immunotherapy of Advanced Melanoma

Current Treatment Options in Oncology, 2012
Adoptive cell therapy (ACT) has emerged as an effective therapy for patients with metastatic melanoma. Since the first introduction of the protocol in 1988 [1], major improvements have been achieved with response rates of 40%-72% among patients who were resistant to previous treatment lines.
Ronnie, Shapira-Frommer, Jacob, Schachter   +1 more
openaire   +2 more sources

Adoptive Immunotherapy for Hodgkin's Lymphoma

International Journal of Hematology, 2006
Adoptive transfer of tumor-specific T-cells is an attractive strategy for the treatment of patients with refractory or relapsed Hodgkin's lymphoma. However, Hodgkin's lymphomas possess a range of tumor-evasion mechanisms, which must be overcome before the full potential of immunotherapies can be achieved.
Alana A, Kennedy-Nasser, Catherine M, Bollard, Cliona M, Rooney   +2 more
openaire   +2 more sources